posted on 2020-11-06, 16:18authored byEleftheria Zeggini, Anna L. Gloyn, Anne C. Barton, Louise V. Wain
Translational genomics aims to improve human health by building on discoveries made through genetics research and applying them in the clinical setting. This progress has been made possible by technological advances in genomics and analytics and by the digital revolution. Such advances should enable the development of prognostic markers, tailored interventions, and the design of prophylactic preventive approaches. We are at the cusp of predicting disease risk for some disorders by means of polygenic risk scores integrated with classical epidemiological risk factors. This should lead to better risk stratification and clinical decision-making. A deeper understanding of the link between genome-wide sequence and association with well-characterized phenotypes will empower the development of biomarkers to aid diagnosis, inform disease progression trajectories, and allow better targeting of treatments to those patients most likely to respond.
Funding
ALG is a Wellcome Trust Senior Fellow Basic Biomedical Science. ALG is funded by the
Wellcome Trust (095101, 200837, 106130, 203141), Medical Research Council (MR/L020149/1),
European Union Horizon 2020 Programme (T2D Systems), and NIH (U01-DK105535; U01-DK085545)
and by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC).
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the
Department of Health. ACB is an NIHR Senior Investigator and supported by the NIHR Manchester
Biomedical Research Centre. LVW holds a GSK/British Lung Foundation Chair in Respiratory
Research. The authors are grateful to Dr. Iris Fischer for helpful edits.
The file associated with this record is under embargo until publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.